Developing pharmacodynamic (PD) biomarker assays for RNA therapeutics targeting liver diseases requires a robust bioanalytical framework. The primary objective is to generate GxP-compliant data packages that quantify target protein knockdown and downstream pathway modulation, directly supporting IND-enabling studies and de-risking clinical translation. We focus on multi-platform assay development, including ligand binding assays and mass spectrometry, to build a comprehensive understanding of in vivo therapeutic effect.
What are the typical sample matrices for liver-targeted RNA PD biomarker analysis?
The primary matrices are serum and plasma for circulating protein targets and functional markers. For direct assessment of target engagement within the liver, tissue biopsies are analyzed using quantitative protein expression techniques and histology.
Which assay platforms are recommended for quantifying target protein knockdown?
We recommend a fit-for-purpose approach. Ligand binding assays, such as ELISA and Meso Scale Discovery (MSD), are suitable for high-throughput quantification of secreted proteins. For intracellular targets or when absolute quantification is required, targeted LC-MS/MS provides superior specificity and precision.
How do you ensure assay specificity for novel RNA therapeutics?
Assay specificity is confirmed during GxP validation. This involves rigorous testing for interference from the therapeutic compound, its potential metabolites, and endogenous matrix components. We develop assays that precisely measure the target protein without cross-reactivity.
Can you measure both on-target engagement and downstream biological effects?
Yes. Our strategy involves developing parallel or multiplexed assays. For instance, we can simultaneously quantify the knockdown of a target protein like PCSK9 while also measuring its direct functional consequence, such as changes in circulating LDL cholesterol levels, providing a complete PD profile.
